Intraperitoneal EMLA (lidocaine/prilocaine) to prevent abdominal adhesion formation in a rat peritonitis model.
OBJECTIVE
The accelerative effect of EMLA (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) in the wound healing process is known. We hypothesised that post-operative peritoneal adhesions may be reduced with intra-peritoneal EMLA administration in a model of bacterial peritonitis.


METHODS
Bacterial peritonitis was induced in 24 rats by cecal ligation and puncture. The rats were randomly assigned to one of four groups. Group 1 (n=6)) received EMLA intraperitoneally, group 2 (n=6) received 2% lidocaine hcl solution intraperitoneally, the third group received one dose (100 mg/kg) of ceftriaxone sodium (Rocephin, Roche, 1 g) intraperitoneally one day after cecal ligation and puncture procedure, and in control group (group 4, n=6), no fluid or medicine was introduced into the abdomens of the rats. All animals were killed 14 days later in order to assess the adhesion score. Tissue antioxidant levels were measured in 1 g tissue samples taken from the abdominal wall.


RESULTS
The adhesion score was significantly lower in the EMLA group than in the lidocaine and control groups. The catalase levels were higher in the lidocaine and control groups than in EMLA group.


CONCLUSIONS
Intraperitoneal EMLA inhibited the formation of postoperative intra-abdominal adhesions without compromising the wound healing in this bacterial peritonitis rat model. EMLA also decreased the oxidative stress during peritonitis (Tab. 1, Fig. 7, Ref. 27). Full Text (Free, PDF) www.bmj.sk.
Department of General Surgery, Faculty of Medicine, Kahramanmaras Sutcuimam University, Kahramanmaras, Turkey. f_vuzbasioglu@hotmail.com
Mehmet Fatih
MF
Yuzbasioglu
Fikret
F
Ezberci
Nimet
N
Senoglu
Pinar
P
Ciragil
Fatma Inanc
FI
Tolun
Hafize
H
Oksuz
Ali
A
Cetinkaya
Yalcin
Y
Atli
Ilhami Taner
IT
Kale
D019162:Anesthetics, Combined / Q000008:administration & dosage*; D000779:Anesthetics, Local / Q000008:administration & dosage*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002443:Ceftriaxone / Q000008:administration & dosage; D005260:Female; D008012:Lidocaine / Q000008:administration & dosage*; D000077442:Lidocaine, Prilocaine Drug Combination; D018384:Oxidative Stress; D010532:Peritoneal Diseases / Q000473:pathology / Q000517:prevention & control*; D010538:Peritonitis / Q000378:metabolism / Q000503:physiopathology*; D011318:Prilocaine / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000473:pathology / Q000517:prevention & control; D014945:Wound Healing / Q000187:drug effects
D019162:Anesthetics, Combined; D000779:Anesthetics, Local; D000900:Anti-Bacterial Agents; D000077442:Lidocaine, Prilocaine Drug Combination; D011318:Prilocaine; D002443:Ceftriaxone; D008012:Lidocaine